ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2008
Genetic changes in small cell lung carcinoma.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Cells · 2020Pooled it
- Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions.Journal of translational medicine · 2023Review
- Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies.Cancer science · 2023Article
- In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer.Clinical and translational medicine · 2022Article
- Potential of Stem Cells and CART as a Potential Polytherapy for Small Cell Lung Cancer.Frontiers in cell and developmental biology · 2021Review
- Immunotherapy as a treatment for small cell lung cancer: a case report and brief review.Translational lung cancer research · 2020Article
- Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer.Journal of oncology · 2020Article
- Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.Molecular medicine reports · 2018Article
- PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017Article
- Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.PLoS genetics · 2016Article
- Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.Journal of cancer research and clinical oncology · 2015Article
- Novel therapies in small cell lung cancer.Translational lung cancer research · 2015Review
- Small cell lung cancer: will recent progress lead to improved outcomes?Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Review
- MET and Small-Cell Lung Cancer.Cancers · 2014Review
- Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2014Article
- Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.Nature medicine · 2014Article
- Staurosporine and extracellular matrix proteins mediate the conversion of small cell lung carcinoma cells into a neuron-like phenotype.PloS one · 2014Article
- Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.PloS one · 2013Article
- Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.BMC systems biology · 2013Article
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.Nature genetics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung carcinoma (SCLC) accounts for approximately 15% of all lung cancer cases. Despite a frequently good response to first-line treatment with chemotherapy and/or radiotherapy, early relapse occurs in the majority of patients and 5-year survival is only about 5%. Therefore, there is a need to develop novel treatments to improve the outcome of patients with SCLC. To fulfil this need, it is critical to gain further understanding on the molecular basis of SCLC and specifically to identify novel therapeutic targets. Clinical trials with molecularly targeted agents have been performed with little success in the past, but recently many promising oncogenic pathways have been discovered and novel targeted therapies are under evaluation. In this review, we summarise the most relevant genetic and signalling pathway alterations reported to date in SCLC and discuss the potential therapeutic implications of such events.
Indexed as
Identifiers
18411191What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.